Covered recipient · General Payments record
TWANA JAFF
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2022–2024
$588.55
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $319.85 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $97.43 | 6 |
| Vanda Pharmaceuticals Inc. | $53.09 | 2 |
| Amgen Inc. | $47.90 | 3 |
| E.R. Squibb & Sons, L.L.C. | $34.71 | 2 |
| Astellas Pharma US Inc | $34.30 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $18.59 | 1 |
| Medtronic, Inc. | $17.27 | 1 |
| GlaxoSmithKline, LLC. | $16.56 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $19.18 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116065249 | CMS |
| Amgen Inc. | $15.40 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117669349 | CMS |
| Amgen Inc. | $13.32 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116065243 | CMS |
| Astellas Pharma US Inc | $34.30 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139331510 | CMS |
| Boston Scientific Corporation | $18.59 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092348755 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.84 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101297317 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.87 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101297349 | CMS |
| GlaxoSmithKline, LLC. | $16.56 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116732624 | CMS |
| Medtronic, Inc. | $17.27 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119543745 | CMS |
| PFIZER INC. | $13.88 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131665216 | CMS |
| PFIZER INC. | $14.02 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131484073 | CMS |
| PFIZER INC. | $17.49 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131877018 | CMS |
| PFIZER INC. | $18.95 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131945478 | CMS |
| PFIZER INC. | $16.87 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131926946 | CMS |
| PFIZER INC. | $16.22 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131190726 | CMS |
| Vanda Pharmaceuticals Inc. | $31.47 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133907483 | CMS |
| Vanda Pharmaceuticals Inc. | $21.62 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133907485 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.